Rapid Molecular Diagnosis of Sepsis in the Intensive Care Unit

Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Oct 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new method for quickly diagnosing sepsis, a serious condition caused by infections in the bloodstream. Currently, the standard method for diagnosing sepsis involves blood cultures, which can take anywhere from 48 hours to 5 days to get results. This delay can make it hard for doctors to provide the right treatment, leading to the use of broad-spectrum antibiotics that might not be necessary. The goal of this trial is to develop a faster test that can detect the DNA of bacteria causing sepsis, helping doctors identify the right treatment sooner and potentially saving lives.

To participate in this trial, patients need to be those for whom doctors are already ordering blood cultures to check for bloodstream infections. There are no specific exclusions, which means many patients who meet the inclusion criteria may be eligible. If you or a family member are involved in this study, you can expect to provide blood samples for testing. This new approach could lead to more accurate and timely treatment for sepsis, which is crucial for improving outcomes and reducing the risk of complications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -Patients are included when routine blood cultures are ordered for diagnosis of bloodstream infections.
• Exclusion Criteria:
• • -N/A